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Abstract 
Vanadium complexes have been previously utilised as potent inhibitors of cysteine based 
phosphatases (CBPs). Herein, we present the synthesis and characterisation of two new 
fluorescently labelled vanadyl complexes (14 and 15) with bridged di-picolinic acid ligand. 
These compounds differ significantly from previous vanadyl complexes with phosphatase 
inhibition properties in that the metal-chelating part is a single tetradentate unit, which should 
afford greater stability and scope for synthetic elaboration then the earlier complexes.  These 
new complexes inhibit a selection of cysteine based phosphatases (CBPs) in the nM range 
with some selectivity. Fluorescence spectroscopic studies (including fluorescence anisotropy) 
were carried out to demonstrate that the complexes are not simply acting as vanadyl delivery 
vehicles but they interact with the proteins. Finally, we present preliminary fluorescence 
microscopy studies to demonstrate that the complexes are cell permeable and localise 
throughout the cytoplasm of NIH3T3 cells. 
  
Introduction 
Cysteine based phosphatases (CBPs) are a large family of enzymes that are defined by a 
cysteine containing motif (CX5R) in their active site and include the protein tyrosine 
phosphatases (PTPs) and inositol lipid phosphatases
1
. While the former counteract the action 
of tyrosine protein kinases the latter balance inositol lipid kinases.
2,3
 Both play an important 
role in the regulation of phosphorylation in cells, which in turn impacts cellular signalling 
and function.
3,4
 Mutation or dysfunction of many members of this family of enzymes have 
been implicated in a range of diseases including immune and neurodegenerative disorders, 
cancer, diabetes and obesity, as well as having a role in inflammatory responses.
5,6
 Given the 
importance of CBPs in disease progression, they are regarded as interesting targets for drug 
development, with a variety of inhibitors being reported.
5,7-14
 One subset of these inhibitors 
are metal ions and their complexes including vanadium, zinc, copper and others, which have 
shown potent inhibition of PTPs in vitro and in vivo.
11,15-19
 In particular, a variety of 
complexes with both vanadium(IV) and vanadium(V) centres have been developed and 
characterised for their CBP inhibition properties
7,10,20-27
 including several examples with 
picolinic acid and its derivatives as ligands.
28-33
 The potency of these inhibitors against PTPs 
and lipid phosphatases can be tuned as a function of the ligand, the vanadium coordination 
number and the oxidation state. For example, the vanadyl complexes V
IV
O(picolinic acid)2 
and V
IV
O(3-hydroxypicolinic acid)2 (1 and 2, Fig.1) have been shown to inhibit specific 
phosphatases at nanomolar concentrations.
29,31
  
 Using as a starting point vanadyl-picolinate complexes such as 1 and 2, we were 
interested in developing novel inhibitors for PTPs and lipid phosphatases with improved 
features. We hypothesised that more robust vanadyl complexes could be obtained by using 
ligands where the two picolinic acids were covalently linked by an appropriate spacer to yield 
a tetradentate ligand (Fig. 2). Furthermore, the linker would offer the potential for further 
chemical functionalisation, such as allowing addition of a fluorophore to track cellular uptake 
and localisation of the resulting vanadyl complexes. Thus, herein we report on the synthesis 
and characterisation of two new fluorescently labelled di-picolinic acid ligands (8 and 13, 
Fig. 2) and the corresponding vanadyl complexes (14 and 15, Fig. 3). We demonstrate that 
addition of the complexes to PTPs and lipid phosphatase leads to inhibition (in the nM range) 
of the enzymes’ activity. We also show by fluorescence microscopy that the complexes are 
cell permeable.   
 
 
Fig. 1  Known vanadyl complexes with PTP and lipid phosphatase inhibitory properties.  
 
 
Results and Discussion 
Synthesis of ligands  
The two new tetradentate ligands (8 and 13) were synthesised as shown in Fig. 2. 5-
hydroxypicolinic acid methyl ester (3)
34
 was reacted with the corresponding Boc-protected 
di-alcohol (4 or 9) via a Mitsunobu reaction using diethyl azodicarboxylate and 
triphenylphosphine. In both cases, after initial purification by column chromatography, the 
products (5 and 10) were obtained as a mixture with triphenylphosphine oxide. Optimisation 
of chromatographic conditions reduced the amount of triphenylphosphine oxide but it could 
not be removed completely. The crude materials were used in the de-protection step which, 
after purification, yielded the corresponding amines 6 and 11 as pure compounds (as 
confirmed by 
1
H NMR spectroscopy and mass spectrometry). The dansyl fluorophore was 
introduced via sulfonylation under anhydrous conditions in the presence of triethylamine to 
obtain 7 and 12, which were taken forward to the final step for removal of the methyl 
protecting groups to give the corresponding ligands 8 and 13. The formation of the desired 
products was confirmed by 
1
H NMR spectroscopy (Fig. S1 and S2, Supporting Information) 
through the disappearance of the methyl peaks (at ca. 3.9 ppm); mass spectrometry provided 
further evidence for the formation of both 8 and 13. Fluorescence emission spectroscopy 
confirmed the presence of the dansyl fluorophore in both the diethanolamine (8, Fig. S3 
Supporting Information) and dipropanolamine (13) linked ligands with emission maxima at 
538 nm and 528 nm respectively.  
 
Fig. 2  Synthesis of fluorescently labelled ligands 8 and 13. 
 
 Synthesis of vanadyl complexes 
In order to prepare the vanadyl complexes, the corresponding ligand was dissolved in water 
(in the presence of NaHCO3) and an aqueous solution of vanadyl sulphate slowly added. A 
clear change from a yellow solution to a dark green suspension was observed upon addition 
of VOSO4 to the ligand. The new vanadyl complexes 14 and 15 were obtained as dark green 
solids and were characterised by spectroscopic and analytical techniques. MALDI-TOF mass 
spectrometry showed peaks corresponding to [M+Na]
+
 in each case. The IR spectra of the 
two complexes shows peaks for the ligand at 1645-1572 cm
-1
 (which can be assigned to C=O, 
C=C and C=N) as well as a strong peak at 965 cm
-1
 and 961 cm
-1
 (assigned to V=O) for 14 
and 15 respectively (Table 1). The formulation and purity of the complexes was confirmed by 
elemental analyses. Both vanadyl complexes are fluorescent (Table 1) although their 
emission intensities are lower than those of the corresponding free ligands.    
 
 
Fig. 3  Synthesis of vanadyl complexes 14 and 15 from the corresponding ligands (8 and 13) and 
vanadyl sulphate.  
 
 
 
Table 1. Spectroscopic data for vanadyl complexes. The IR data was recorded using a solid sample 
of the corresponding compound while UV/Vis and emission spectroscopic data was collected using 
solutions in methanol (14 and 15 at 30 µM, 1 at 15 µM and 2 at 45 µM). Fluorescence data was 
recorded in Tris buffer (30 µM).  
 
 
 
 
 
 
 
 
Phosphatase inhibition assays 
In order to characterise the inhibitory potency of 14 and 15, phosphatase inhibition assays 
against a selection of PTPs (PTP1B, LMW-PTP, VHR and SHP-2 – see Table 2 for 
abbreviations) as well as the inositol lipid phosphatase PTEN were carried out employing 3-
O-methylfluorescein phosphate (OMFP) as a substrate.
28
 As shown in Table 2 compounds 14 
and 15 inhibit all PTPs tested in the mid to high nanomolar range, which is consistent with 
the inhibitory potency previously reported for compound 1 (Fig 1).
29,31
 The IC50 value for 14 
against LMW-PTP and PTEN is significantly higher than for the other enzymes while 
complex 15 has a significantly lower IC50 value for PTP1B than for any other of the tested 
phosphatases. These observations suggest that the complexes show some selectivity towards 
certain PTPs compared to others. There also seems to be an effect on the inhibitory properties 
of the complex on increasing the length of the linker from diethanolamine (14) to 
dipropanolamine (15) for VHR, SHP2, and LMW-PTP. The IC50 values for VHR and SHP2 
Compound 
IR 
(V=O)/cm
-1
 
UV-vis λmax /nm 
(ε/ M-1 cm-1) 
Fluorescence 
λmax(em)/nm 
14 965 263 
(4.86×10
4
) 
568 
15 961 262 
(7.37×10
4
) 
566 
1 962 266 
(7.78 ×10
3
) 
- 
2 954 305 
(9.8×10
3
) 
- 
are around two to three fold higher for compound 15 than 14 whereas the IC50 is reduced 
against LMW-PTP on increasing linker length. This suggests that varying the linker length 
could be used as a method to tune selectivity of the complex as the effect differs across the 
CBPs. As a control, we also carried out the inhibition studies with the free ligands (8 and 13) 
using VHR and LMW-PTP as representative examples of the phosphatases. No inhibition 
was observed up to a 1 μM concentration of the ligand and only minor effects were observed 
at 10 μM (Fig. S6 and S7, Supporting Information); this indicates that the free ligand does not 
contribute to the IC50 values reported in Table 2. We also carried out the inhibition studies 
using VOSO4 as a control. As can be seen in Table 2, the inhibitor profile for VOSO4 did not 
match with the one observed for compounds 14 and 15. For example, VOSO4 is more potent 
against SHP2, but significantly less potent for PTP1B, which is not what one would expect if 
the complexes are a delivery mechanism for vanadyl itself. Thus, the data suggests that 14 
and 15 are not acting simply as a vanadyl delivery vehicle. This notion was explored in more 
depth using spectroscopy means (see next section).    
 
Table 2 IC50 values (nM) of vanadyl complexes 14 and 15 (the data shown is ±standard deviation of 
triplicate repeats) 
 
 
PTEN = Phosphatase and tensin homolog. PTP1B = Protein-tyrosine phosphatase 1. SHP-2 = Src homology 
region 2 domain-containing phosphatase-2. LMW-PTP = Low molecular weight protein tyrosine phosphatase. 
VHR = dual specificity protein phosphatase 3. For assay conditions see experimental section.  
 
Compound PTEN
 
PTP1B
 
VHR SHP2 LMW-PTP 
14 211±33 94±43 72±10 77±27 177±7 
15 222±49 84±23 130±14 162±20 120±12 
VOSO4 - 151±16 120±60 71±80 117±40 
Effects of enzyme on the fluorescence of vanadyl complexes 
Having shown that the potency of 14, 15 and VOSO4 for the selected PTPs is close to each 
other, it was of interest to corroborate the conclusion drawn from the data presented in table 
2. In order to investigate the integrity of the complexes in the enzyme assays, we made use of 
the dansyl moiety within the ligand in a number of fluorescence spectroscopic studies. Upon 
coordination of vanadyl to ligands 8 and 13, the emission of the dansyl decreases, which can 
be employed to monitor the integrity of the complexes while interacting with the enzymes. 
Therefore, we first studied whether the fluorescence of the ligand in complex 14 could be 
recovered by removing the vanadyl from the corresponding complex with EDTA, a strong 
vanadyl chelator.
23
 As can be seen in Figure 4, addition of an excess of EDTA (1 mM) to 
complex 14 (30 µM), restored the fluorescence of the ligand in the absence of enzyme. 
Having established that EDTA can indeed remove vanadyl from the complexes and in doing 
so change the fluorescence of the ligand, we investigated the effect of LMW-PTP (as a 
representative example of the PTPs) on the emission of complex 14. As can been seen in 
Figure 4, incubation of 14 with LMW-PTP did not restore the emission of the ligand which 
suggests that the vanadyl is still coordinated to ligand 8 in the presence of the enzyme. A 
control experiment was carried out in which the compound was incubated with both EDTA 
and the enzyme and the emission intensity compared to that of the corresponding ligand 
under the same conditions. Interestingly, in this case full restoration of the emission was not 
observed after 5 minutes incubation (see Fig. S4, Supplementary Information) in spite of the 
presence of EDTA. Complete restoration was, however, observed after 2 hours incubation 
(see Fig. 4). These experiments were also carried out with ligand 13 and complex 15 and the 
same pattern of results was observed (see Fig S5, Supplementary Information, i.e. 2 hours 
incubation).  
Taken together these observations imply that the enzyme LMW-PTP binds to the 
intact complex (as defined by the vanadyl being near the fluorophore-ligand) and in doing so 
‘protects’ the tightly bound complexes from EDTA. However, we cannot rule out the 
possibility that the vanadyl, while still bound to the ligand, may form new interactions with 
the enzymes, which would imply that the vanadyl would exchange partially coordination sites 
between ligand and enzyme. We should also note that the interaction between the vanadium 
complexes and the Tris buffer used in these studies is unlikely to affect the observations. 
Previous studies have shown that such interactions are weak (i.e. high mM).
35
 Furthermore, 
as we have demonstrated in this study, EDTA is required to remove the vanadium centre 
from the complex (in Tris buffer). Consequently, under the conditions of our studies, Tris is 
an appropriate buffer. 
 
Fig.4 Fluorescence intensity at 560 nm of a 30 µM solution of ligand 8 and complex 14 in the 
presence or absence of LMW-PTP (Enz) and 1 mM EDTA in Tris buffer containing 1 mM DTT. Reading 
was taken after 2 hours incubation at room temperature. Intensity is recorded ±standard deviation 
of triplicate repeats. A statistical analysis has been performed showing that the difference between 
the fluorescence intensity of 8 and 14 incubated with enzyme in the absence of EDTA (1st and 3rd bar 
pairs in this figure) are statistically significant (*p < 0.05).  
 
To investigate this further, we carried out fluorescence anisotropy studies of complex 
14 in the presence and absence of LMW-PTP (as model enzyme). This type of studies is 
widely used to investigate the interaction between an emissive molecule and large bio-
molecules (such as proteins). This technique relies on the change in rotational correlation 
time of the fluorophore (in this case our dansyl-labelled vanadyl complex) upon interaction 
with a large molecule (in this case LMW-PTP). As can be seen in Fig. 5(a), addition of the 
enzyme to the complex led to an increase in the fluorescence anisotropy (reaching a 
maximum at ca. 2 equivalents of the enzyme) consistent with an interaction of the complex 
with the enzyme.  
We then investigated the effect that EDTA has on the fluorescence anisotropy of 
complex 14 pre-bound to LMW-PTP. As Fig. 5(b) shows, the fluorescence anisotropy was 
reduced within an hour to the level of the enzyme-free sample suggesting that when the 
vanadyl is sequestered by the EDTA the fluorescent ligand no longer associates with the 
enzyme. Control studies with the free ligand were also carried out. The fluorescence 
anisotropy of 8 under the same experimental conditions (see caption in Fig. 5) was 0.20 and 
in the presence of enzyme (36 μM) was 0.21. This clearly demonstrates that the free ligand 
does not interact with the enzyme and therefore the changes observed with complex 14 are 
due to binding of the complex with the protein.   
 
Fig.5 (a) Fluorescence anisotropy of 14 (10 µM) in the presence of increasing concentrations of 
LMW-PTP (0-36 µM). (b) Fluorescence anisotropy of 14 (10 µM) in the absence or presence of LMW-
PTP and over 100 minutes of incubation with the enzyme and 1 mM EDTA. Readings were taken in 
100mM Tris buffer solution with 1mM DTT in a 200µL fluorescence cuvette. Excitation wavelength is 
340 nm, emission recorded at 560 nm. The error is shown as the standard deviation of 6 readings 
from two independent experiments. Significant differences (5% cut-off for significance) to the 
“buffer + compound” data are indicated by stars (* p < 0.05; ** p < 0.01; *** p < 0.001). The blank 
control used 50% glycerol in elution buffer to mimic the enzyme solution as the viscosity of the 
mixture would have an effect on the polarisation.  
 
 
The spectrofluorimetric data shown in Figures 4 and 5 clearly indicate that the 
complex does not break completely apart in the presence of the enzyme under physiological 
conditions. There have been extensive studies in the literature aimed at understanding the 
mode of action of vanadium complexes in the context of their CBP inhibition properties. 
There is considerable evidence suggesting that such complexes act as prodrugs releasing the 
active vanadium species in biological media.
36
 Interestingly our data suggests that, under the 
conditions used, the vanadium complexes do not break apart completely. 
 
 
Cellular uptake studies 
In order for the complexes 14 and 15 to be utilised as PTPs inhibitors in a cellular 
environment their ability to be taken up into cells would have to be confirmed. Compound 14 
was chosen as a representative complex and thus, NIH3T3 cells were incubated with three 
different concentrations of 14 (1, 5 and 10 μM) for 24 hours at 37 ºC. The cells were 
subsequently analysed by fluorescence microscopy. As can be seen in Fig. 6, the complex 
(green) is widely taken up by cells. Under these conditions, the complex is localised 
throughout the cell, but seems to be enriched in some structures within the nucleus and the 
perinuclear region. This is in agreement with the known subcellular localisation of PTEN and 
VHR, which are known to be present in the perinuclear region as well as the nuclear 
compartment.
37-39
 In contrast, other enzymes that might be targeted by 14 are known to 
localise to the ER/nuclear envelope network (PTP1B),
40
 the cytosol and cytoskeletal 
compartment (LMW-PTP),
41
 or the cytosolic localisation (SHP-2).
39
 While we cannot rule 
out the possibility that the observed localisation of 14 is influenced by other cysteine based 
phosphatases as well, it seems that in the cellular environment 14 is distributed throughout 
the cell in a pattern that matches the phosphatases it is targeting. 
 
Fig. 6 (a) Fluorescence microscopy images showing uptake of 14 (green) by NIH3T3. Cells were 
incubated in media containing 0 μM (control), 1 μM, 5 μM or 10 μM of complex 14 and lastly fixed 
with PFA before imaging. To provide a better perception of the nuclear and perinuclear localisation 
of compound 14 three representative images are presented for each treatment in comparison with 
merge channel images. (b) Quantiﬁcation of ﬂuorescence signal was performed with FIJI. Data for 
the quantiﬁcation are reported as ± SEM and were obtained from a minimum of 3 independent 
experiments counting a total number of cells as follow: 10 (for control), 7 (for 1 μM), 10 (for 5 μM), 
18 (for 10 μM). Significant differences (5% cut-off for significance) to the control data are indicated 
by stars ( *** p < 0.001).  
 
 
Conclusions 
Two new di-picolinic acid-based compounds containing a dansyl fluorophore have been 
prepared and successfully used as ligands to prepare the two novel vanadyl complexes 14 and 
15. Phosphatase inhibition assays showed that the complexes inhibited a selection of 
phosphatases (PTP1B, SHP-2, LMW-PTP, VHR and PTEN) over a concentration range of 
72–222 nM and some selectivity and effect of linker length was observed. The variability in 
inhibition properties, together with fluorescence data for the complexes in the presence and 
absence of EDTA and enzyme indicate that the complexes are not simply acting as vanadyl 
delivery vehicles. On the other hand, based on their large size and saturated coordination 
sphere, it is unlikely that the intact complexes are binding to the enzymes and causing the 
inhibition of their activity. Therefore, we propose that derivatives of complexes 14 and 15 in 
which the ligand (8 and 13 respectively) is partially de-coordinated from the vanadyl centre 
are interacting with the enzymes. A likely possibility could be that one of the picolinate 
‘arms’ of the ligands de-coordinates leaving the vanadyl coordinatevely unsaturated and 
hence able to interact strongly with the enzymes and yet retain the fluorescent ligand (see 
Figure 7) as supported by the fluorescence studies. It has also been shown that the complexes 
are cell permeable and localize in the cytoplasm. The complexes represent a new class of 
tetradentate vanadyl inhibitors that offer the potential for synthetic functionalization. The data 
indicates that these new optically labelled vanadyl complexes have the potential to be 
developed further into potent and potentially selective inhibitors and targeted probes. 
 
 Fig. 7 Schematic representation of a potential binding mode between the vanadyl complexes and 
CBPs.  This proposed interaction – based on the de-coordination of one ‘arm’ of the ligand – is 
consistent with the experimental observations herein presented.  
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Experimental Details 
General spectroscopy and materials. IR spectra were recorded on a Perkin Elmer FT–
IR1720 Research Series spectrometer in the range 4000-600 cm
-1
. Electrospray (ESI+) mass 
spectrometry was run at on a Waters Aquity UPLC I-CLASS coupled with Waters LCT 
Premier (operating in ES+ or ES- mode). MALDI analyses were performed using MicroMass 
MALDI microMX TOF operating in reflectron mode using a 337nm nitrogen laser. NMR 
spectra were recorded on a Bruker spectrometer with d
6
-DMSO (δH = 2.50 ppm, δC = 39.5 
ppm), CD3OD (δH = 3.31 ppm, δC = 49.2 ppm) and CDCl3 (δH = 7.26 ppm, δC = 77.2 ppm) as 
internal references. UV-vis spectra were recorded on a Perkin-Elmer Lambda 25 UV-vis 
spectrometer. Fluorescence data were collected using a Varian fluorescence spectrometer, 
while fluorescence polarisation studies were performed with a Perkin-Elmer LS50B 
Luminescence Spectrometer. Compounds 3, 4, and 9 were prepared according to reported 
procedures.
34,42,43
  
Synthesis of 5. To a solution of 5-hydroxyoxypicolinic acid methyl ester 3 (312 mg, 2.03 
mmol), triphenylphosphine (1.07 g, 4.07 mmol) and N-Boc diethanolamine 4 (209 mg, 1.02 
mmol) in anhydrous THF (15 mL), stirred on ice under N2, was added diethyl 
azodicarboxylate (DEAD, 0.64 mL, 4.07 mmol) in anhydrous THF (1 mL). The resulting 
reaction mixture was stirred at room temperature for 16 hours. The solvent was removed by 
rotary evaporation to give the crude product 5 as an orange oil. The product was purified by 
silica gel column chromatography (70% EtOAc/Hex – 3% MeOH/EtOAc) to yield a mixture 
(ca. 1:0.1) of 5 and triphenylphosphine oxide. This compound was used without further 
purification for the next step. The following spectroscopic data corresponds to the signals 
associated to 5: 
1
H NMR (400 MHz, CDCl3): δ(ppm) 8.37 (d, J = 2.9 Hz, 2H), 8.10 (d, J = 
8.7 Hz, 2H), 7.26 (m,
 
2H), 4.24 (m, 4H), 3.98 (s, 1H,),   3.77 (t, J = 5.4 Hz, 4H), 1.46 (s, 9H). 
13
C NMR (100 MHz, CDCl3): δ(ppm) 165.2 (C), 157.4(C), 155.3 (C), 138.5 (CH), 138.3 
(CH), 127.0 (C), 120.4 (CH), 67.4 (CH2), 52.9 (CH3), 48.2 (CH2), 28.6 (CH3). ESI-MS (+) 
476 ([M+H]
+
) (100%). 
Synthesis of 6. To a solution of 5 (477 mg, 0.87 mmol) in dichloromethane (1 mL) was 
added trifluoroacetic acid (1 mL) and the reaction stirred at room temperature for 1 hour. The 
solvent was removed under reduced pressure and the product purified by silica gel column 
chromatography (EtOAc then MeOH:dichloromethane: NEt3 10:85:5) to give 6 (326 mg, 
0.87 mmol, 100%) as a pale pink solid. 
1
H NMR (400 MHz, CDCl3): δ(ppm) 8.33 (d, J = 2.8 
Hz, 2H), 8.09 (d, J = 8.7 Hz, 2H), 7.52 (dd, J = 8.8, 2.9 Hz, 2H), 4.35 (t, J = 5.0 Hz, 4H), 3.91 
(s, 6H), 3.36 (t, J = 5.0 Hz). 
13
C NMR (100 MHz, CD3OD): δ(ppm) 166.2 (C), 159.0 (C), 
141.2 (CH), 139.5 (CH), 127.9 (C), 122.2 (CH), 67.5 (CH2), 53.0 (CH3), 47.9 (CH2). IR in 
cm
-1
 υ(C-H)/υ(N-H) 3059-2955, υ(C=N)/υ(C=C) 1735, 1668,1623, 1578, υ(C-O) 1303. LC-
MS(+) 377 ([M+H]
+
) (100%).  
Synthesis of 7. To a solution of 6 (100 mg, 0.27 mmol) and dansyl chloride (87 mg, 0.32 
mmol) in anhydrous acetonitrile (8.5 mL) was added anhydrous triethylamine (0.08 mL, 0.54 
mmol) and the reaction stirred at room temperature for 16 h. The solvent was removed by 
rotary evaporation to give a yellow residue. The crude mixture was purified by silica gel 
column chromatography (2% MeOH in dichloromethane) to give the desired product 7 (83 
mg, 0.14 mmol, 50%) as a yellow/green oil. 
1
H NMR (400 MHz, CD3OD): δ(ppm) 8.50 (dt, J 
= 8.6, 1.0 Hz, 1H), 8.24 (dd, J = 7.3, 1.2 Hz, 1H), 8.21-8.18 (m, 1H),  8.01-7.90 (m, 4H), 7.52 
(dd, J = 8.5, 7.3 Hz, 1H) 7.41 (dd, J = 8.7, 7.6 Hz, 1H), 7.19 (dd, J = 8.8, 2.9 Hz, 2H), 7.13 
(dd, J = 7.7, 0.8 Hz, 1H), 4.21 (t, J =  5.2 Hz, 4H), 3.91 (m, 10H),  2.81 (s, 6H).
 13
C NMR 
(100 MHz, CD3OD): δ(ppm) 166.2 (C), 158.8 (C), 153.2 (C), 140.8 (CH), 139.3 (CH), 136.1 
(C), 131.9 (C), 131.3, 131.2 (CH), 131.1 (CH), 129.2 (CH), 127.7 (C), 124.3 (CH), 121.8 
(CH), 120.5 (C), 116.4 (CH), 68.2 (CH2), 53.0 (CH3), 45.7 (CH2). ESI-MS (+) 609 
([M+H]
+
). IR in cm
-1
 υ(C=N)/υ(C=C) 1715, 1573.  
Synthesis of 8. To a solution of 7 (196 mg, 0.32 mmol) in THF:MeOH (0.8:0.3 mL) on ice 
was added 6M NaOH (0.15 mL, 0.90 mmol) and the reaction stirred for 3 hours at room 
temperature. The solvent was removed by rotary evaporation to give a bright yellow solid 
which was diluted with water and extracted with ethyl acetate. The organic layer was set 
aside and the aqueous layer acidified with 2M HCl and re-extracted with EtOAc (4 x 10 mL). 
The organic layers were combined, dried over Mg2SO4 and the solvent removed by rotary 
evaporation to give the desired product 8 (98.5 mg, 0.17 mmol, 53%) as a yellow solid. 
1
H 
NMR (400 MHz, CD3OD): δ(ppm) 8.51 (d, J = 8.6 Hz, 1H), 8.25 (d, J = 7.4, 1.2 Hz, 1H), 
8.20 (d, J = 8.7 Hz, 1H),  8.06-7.92 (m, 4H), 7.53 (dd, J = 8.5, 7.3 Hz, 1H), 7.42 (dd, J = 8.7, 
7.6 Hz, 1H), 7.21 (dd, J = 8.7, 2.9 Hz, 2H), 7.13 (d, J = 7.5 Hz, 1H), 4.21 (t, J =  5.2 Hz, 4H), 
3.93 (t, J =  5.2 Hz, 4H), 2.83 (s, 6H).
 13
C NMR (100 MHz, DMSO-d
6): δ(ppm) 165.7 (C), 
156.5 (C), 151.4 (C), 140.6 (CH), 137.7 (CH), 134.8 (C), 130.1 (C), 129.4, 129.2 (CH), 
128.9 (CH), 128.1 (CH), 126.1 (C), 123.6 (CH), 120.6 (CH), 118.8 (C), 115.2 (CH), 66.4 
(CH2), 46.8 (CH3), 45.0 (CH2). ESI-MS (+) 581 ([M+H]
+
). IR in cm
-1
 υ(C=N)/υ(C=C) 1690, 
1573, υ(S=O) 1140. Fluorescence in DMF: λmax(ex) 358 nm, λmax(em) 538 nm.  
Synthesis of 14. To a suspension of 8 (167 mg, 0.29 mmol) in water (6 mL) was added 10% 
NaHCO3 (0.51 mL, 0.58 mmol) and the mixture stirred until all solid was dissolved. VOSO4 
(63 mg, 0.29 mmol) in water (4 mL) was added slowly over 2 minutes after which a 
precipitate began to form. The reaction was left to stir for 2 hours. After 1 week without 
stirring a green solid precipitated from the solution. This was collected by filtration and IR 
indicated a vanadyl complex had formed. Further characterisation by mass spectrometry 
indicated this was the desired complex 14 (13 mg, 0.02 mmol, 7%). ESI-MS (+) 668 
([M+Na]
+
). IR in cm
-1
 υ(C=N)/υ(C=C) 1636, 1591, 1575, υ(S=O) 1136, υ(V=O) 965. Calc. 
for C28H26O9N4SV·3H2O: C 48.07, H 4.61, N 8.01 Found: C 48.07, H 4.39, N 7.72. UV-vis 
(MeOH/DMF) λ/nm (ε/M-1·cm-1) 263 (4.86×104), 337 (1.03×104). Fluorescence in Tris 
buffer: λmax(ex) 340 nm, λmax(em) 568 nm. 
Synthesis of 10. To a solution of 5-hydroxypicolinic acid methyl ester 3 (362 mg, 2.36 
mmol), triphenylphosphine (1.24 g, 4.72 mmol) and N-Boc dipropanolamine 9 (276 mg, 1.18 
mmol) in anhydrous THF (18 mL), stirred on ice under N2, was added diethyl 
azodicarboxylate (DEAD, 0.74 mL, 4.72 mmol) in anhydrous THF (1.2 mL) and the reaction 
was stirred at room temperature for 16 h. Solvent was removed by rotary evaporation to give 
the crude product 10 as an orange oil. The product was purified by silica gel column 
chromatography (80% EtOAc/Hex – 3% MeOH/EtOAc) to yield a mixture (ca. 1:0.2) of 10 
and triphenylphosphine oxide. This compound was used without further purification for the 
next step. The following spectroscopic data corresponds to the signals associated to 10: 
1
H 
NMR (400 MHz, CDCl3): δ(ppm) 8.37 (d, J = 2.9 Hz, 2H), 8.10 (d, J = 8.7 Hz, 2H), 7.24 (dd, 
J = 8.8, 2.9 Hz, 2H), 4.13-4.08 (m, 4H), 3.97 (s, 6H), 3.41 (t, J = 6.9 Hz, 4H), 2.16-2.03 (m, 
4H), 1.39 (s, 9H). 
Synthesis of 11.To a solution of 10 (421 mg, 0.95 mmol) in dichloromethane (1 mL) was 
added trifluoroacetic acid (1 mL) and the reaction stirred at room temperature for 1 hour. The 
solvent was removed and the product 11 isolated pure by silica gel column chromatography 
(EtOAc then MeOH:dichloromethane:NEt3 10:85:5) to give the desired product 11 (279 mg, 
0.67 mmol, 71%) as a pale pink solid. 
1
H NMR (400 MHz, d6-DMSO): δ(ppm) 8.37 (d, J = 
2.8 Hz, 2H), 8.03 (d, J = 8.7 Hz, 2H), 7.50 (dd, J = 8.8, 2.9 Hz, 2H), 4.21 (t, J = 6.2 Hz, 4H), 
3.84 (s, 6H), 2.91 (t, J = 7.1 Hz, 4H), 2.00 (m, 4H). 
13
C NMR (100 MHz, d6-DMSO): δ(ppm) 
164.8 (C), 157.2 (C), 139.5 (CH), 139.4 (CH), 126.4 (C), 120.6 (CH), 66.1 (CH2), 52.1 
(CH3), 44.9 (CH2), 27.1 (CH2). IR in cm
-1
 υ(N-H) 2804, υ(C=N)/υ(C=C) 1732, 1669, 1574, 
υ(C-O) 1316. ESI-MS (+) 404 ([M+H]+), 426 ([M+Na]+). 
Synthesis of 12. To a solution of 11 (270 mg, 0.67 mmol) and dansyl chloride (217 mg, 0.80 
mmol) in anhydrous acetonitrile (21 mL) was added anhydrous triethylamine (0.28 mL, 2.0 
mmol) and the reaction stirred at room temperature for 48 h. The solvent was removed by 
rotary evaporation to give a yellow residue. The crude mixture was purified by silica gel 
column chromatography (2- 3% MeOH in dichloromethane) to give the desired product 12 
(317 mg, 0.50 mmol, 75%) as a yellow solid.. 
1
H NMR (400 MHz, CD3OD): δ(ppm) 8.26 (dt, 
J = 8.6, 1.0 Hz, 1H), 8.21 (dd, J = 7.4, 1.2 Hz, 1H), 8.13 (d,
 
J = 8.7, 0.9 Hz, 1H),  8.04 (d, J = 
2.9 Hz, 2H), 7.99 (d, J = 8.8 Hz, 2H), 7.54-7.46 (m, 2H), 7.12 (dd, J = 8.7, 2.9 Hz, 2H), 7.09 
(d, J = 7.7, 0.8 Hz, 1H), 3.96-3.93 (m, 10H), 3.59 (t, 4H,
 
J = 6.7 Hz),  2.77 (s, 6H) 2.08 (m, 
4H). 
13
C NMR (100 MHz, CD3OD): δ(ppm) 166.3 (C), 159.1 (C), 153.1 (C), 140.5 (CH), 
139.3 (CH), 135.3 (C), 131.9 (C), 131.7, 131.2 (CH), 130.9 (CH), 129.2 (CH), 127.7 (C), 
124.1 (CH), 121.6 (CH), 120.0 (C), 116.0 (CH), 66.7 (CH2), 53.0 (CH3), 45.7 (CH2), 43.6 
(CH2), 28.0 (CH2). ESI-MS (+) 637 ([M+H]
+
), 659 ([M+Na]
+
). 
Synthesis of 13. To a solution of 12 (317 mg, 0.50 mmol) in THF:MeOH (1.3:0.5 mL) on ice 
was added 6M NaOH (0.23 mL, 1.90 mmol) and the reaction stirred for 3 h at room 
temperature. The solvent was removed by rotary evaporation to give a pale yellow solid 
which was diluted with water and extracted with ethyl acetate. The organic layer was set 
aside and the aqueous layer acidified with 6M HCl and re-extracted with EtOAc (3×6 mL) 
and dichloromethane (1 × 6 mL). The organic layers were combined, dried over Mg2SO4 and 
the solvent removed by rotary evaporation to give the desired product 13 (157 mg, 0.26 
mmol, 52%) as a yellow solid. 
1
H NMR (400 MHz, CD3OD): δ(ppm) 8.27 (d, J = 8.5 Hz, 
1H), 8.22 (d, J = 7.4 Hz, 1H), 8.14 (d, J = 8.4 Hz, 1H), 8.06 (d, J = 2.8 Hz, 2H), 8.02 (d, J = 
8.8 Hz, 2H), 7.54-7.48 (m, 2H), 7.17 (dd, J = 8.7, 2.9 Hz, 2H), 7.12 (d, J = 7.6 Hz, 1H), 3.96 
(t, J =  5.8 Hz, 4H), 3.60 (t, 4H, J = 6.8), 2.79 (s, 6H), 2.12 – 2.05 (m, 4H). 13C NMR (100 
MHz, d
6
-DMSO): δ(ppm) 165.7 (C), 156.8 (C), 151.4 (C), 140.3 (CH), 137.7 (CH), 134.2 
(C), 130.1 (C), 129.4, 129.3 (CH), 129.1 (CH), 128.1 (CH), 126.1 (C), 123.5 (CH), 120.4 
(CH), 118.5 (C), 115.0 (CH), 65.4 (CH2), 45.0 (CH2), 43.1 (CH2), 27.0 (CH2). ESI-MS (+) 
609 ([M+H]
+
). Fluorescence in DMF: λmax(ex) 340 nm, λmax(em) 528 nm. 
Synthesis of 15. To a suspension of 13 (150 mg, 0.25 mmol) in water (6 mL) was added 10% 
NaHCO3 (0.44 mL, 0.49 mmol) and the mixture stirred until all solid was dissolved. A 
solution of VOSO4 (53.5 mg, 0.25 mmol) in water (3.5 mL) was added slowly over 2 minutes 
after which a precipitate began to form. The reaction was left to stir for 2 hours. After 2 days 
without stirring a green solid had precipitated from the reaction solution which was collected 
by filtration and IR indicated a vanadyl complex had formed. Further characterisation by 
mass spectrometry indicated this was the desired complex 15 (42 mg, 0.06 mmol, 25%). ESI-
MS (+) 696 ([M+Na]
+
).  IR in cm
-1
 υ(C=N)/υ(C=C) 1645,1591, 1572, υ(S=O) 1134, υ(V=O) 
961. Calc. for C30H30O9N4SV·3.5H2O: C 48.92, H 5.06, N 7.61 Found: C 48.62, H 4.71, N 
7.39. UV-vis (MeOH/DMF) λ/nm (ε/M-1·cm-1) 262 (7.37×104), 340 (1.30×104). Fluorescence 
in Tris buffer: λmax(ex) 340 nm, λmax(em) 566 nm. 
CBP Expression and Purification. PTP1B, VHR, SHP2 and LMW-PTP were expressed as 
GST-fusion proteins. The protocol followed was: the corresponding RNA was extracted 
using PureLink® RNA Mini Kit from Invitrogen (according to manufacturer's protocol) from 
HEK293 cells. First DNA synthesis was performed using ProtoScript® First Strand cDNA 
Synthesis Kit from New England Biolabs according to manufacturer's protocol. In a second 
round of PCR, gene specific primers were used to obtain the DNA for PTEN, PTP1B, VHR, 
SHP2 and LMW-PTP, adding the restriction site BamHI at 5' and XhoI at the 3' end, 
respectively. The obtained DNA fragments were then cloned into pGEX-6P-1 vector using 
the aforementioned restriction sites. All four constructs were validated via DNA sequencing 
to ensure in-frame cloning with the GST tag encoded by the pGEX-6P-1 vector. 
  
Protein expression was induced in the E. coli strain DH5α for 24h using 1 mM IPTG at 23° 
C. After growth the cells were harvested and stored at -20°C.  The harvested cells were 
resuspended in lysis buffer containing 50 mM Tris (pH 7.4), 1% Triton X-100, 10 mM 
benzamidine hydrochloride, 100 µg/mL soybean trypsin inhibitor, 1 mM 4-(2-
Aminoethyl)benzenesulfonyl fluoride hydrochloride and 2 mM DTT. Lysozyme was added 
to the cell suspension at a concentration of 2 mg/mL and stirred for 1 h at 4°C. Lysis was 
completed by sonication, followed by centrifugation at 18000 g for 30 min at 4°C. The 
supernatant was loaded onto a glutathione sepharose column, pre-equilibrated with 50 mM 
Tris (pH 7.4), 140 mM NaCl and 2.7 mM KCl. After loading, the column was washed twice 
with 50 mM Tris (pH 7.4), 140 mM NaCl, 2.7 mM KCl and 2 mM DTT. Another two washes 
were performed using the same buffer with 500 mM NaCl. The GST-tagged phosphatases 
were eluted using 20 mM glutathione in 50 mM Tris (pH 7.4), 250 mM NaCl and 2 mM 
DTT. 50 % glycerol was added and the proteins were stored at -80°C. Protein concentration 
was determined using Bradford assay. 
 
Phosphatase inhibition assays in the absence of EDTA. 3-O-methylfluorescein phosphate 
(OMFP, 10 mM in DMSO) was diluted with a 1% DMSO solution to the required 
concentration. The corresponding vanadyl complexes were dissolved in DMF or DMSO to 10 
mM and further diluted in water containing 1% DMSO to the required concentrations. Assays 
were run in 100 mM Tris (pH7.4) containing 1 mM DTT at room temperature. The inhibitor 
solutions were incubated with the enzyme in the buffer for 10 minutes at room temperature 
before reaction was initiated by addition of OMFP. Hydrolysis of OMFP to OMF was 
monitored by measuring changes in fluorescence over 30 minutes at 60 s intervals (excitation 
485 nm, emission 525 nm) using a Varian fluorescence spectrometer. Enzyme free blanks 
were run to eliminate background effects of OMFP hydrolysis in solution. 
Statistical analysis of enzyme inhibition data.  Statistical comparison of the means (using 
GraphPad Prism 5 or StatPlus, AnalystSoft Inc.) was performed by a two-tailed t-test. A 5% 
cut-off for significance was employed and the degree of significance indicated by stars (i.e. * 
p < 0.05; ** p < 0.01; *** p < 0.001) within the corresponding figures. 
 
 
Changes in fluorescence of complexes in presence of enzyme and/or EDTA. Vanadyl 
compounds were dissolved in DMF to 10 mM and further diluted in buffer containing 1% 
DMSO to 300 µM. Enzyme was added to buffer solution of 100 mM Tris (pH7.4) containing 
1 mM DTT, with or without 1 mM EDTA. Enzyme free controls consisted of buffer solution 
of 100 mM Tris (pH=7.4) containing 1 mM DTT, with or without 1 mM EDTA. In a 96-well 
plate, the inhibitor solutions were added to wells containing one of the above mentioned 
buffers to a final concentration of 30 µM. Fluorescence emission spectra were recorded in the 
range of 380-650 nm after excitation at 340 nm with excitation slit widths of 5-10 nm and 
emission slit widths of 10-20 nm using a Varian fluorescence spectrometer. Readings were 
taken 5 minutes and 2 hours after addition of inhibitor solutions. 
 
Fluorescence Anisotropy Measurements: Vanadium complexes were dissolved in DMSO 
to 10 mM and further diluted in a 1% DMSO solution to the required concentration. A five-
fold excess of enzyme was diluted in an aqueous solution of 1 mM DTT and 100 mM Tris 
(pH 7.4) and incubated with the inhibitor for 10 mins. A 50:50 glycerol-elution buffer 
(100mM Tris, 250 mM NaCl, 20 mM reduced glutathione, 2 mM DTT, pH 7.4) mixture was 
used for the enzyme free control. Samples were then analysed for polarised fluorescence 
emission in a fluorescence cuvette (excitation 340 nm, emission 560 nM). 1mM EDTA was 
then added to the enzyme containing solution and further readings were taken every 15 mins 
for 60 mins and then a final reading at 100 mins.  
Fluorescence Anisotropy Measurements – enzyme titration: Vanadium complexes were 
dissolved in DMSO to 10 mM and further diluted in a 1% DMSO solution to the required 
concentration before mixing with an aqueous solution of 1 mM DTT and 100 mM Tris (pH 
7.4). A fluorescence anisotropy reading was taken at excitation 340 nM, emission 560 nM. 
LMW-PTP was then titrated into the mixture increasing from 0.36 equivalent to 3.6 
equivalents with a fluorescence anisotropy reading taken after 1 min incubation with each 
enzyme addition.  
Cell uptake studies. NIH3T3 cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% newborn calf serum in an atmosphere of 10 % CO2 at 
37ºC.  Cells were seeded in a plastic 24-well plate.  After 16 hours the compound was added 
to the cells in fresh media at 1, 5 and 10 µM (final DMSO concentration 1 % v/v for all 
wells), and incubated for 24 hours at 37ºC and 10% CO2.  The media was then removed and 
the cells washed three times with sterile Dulbecco’s phosphate buffered saline (PBS, EDTA-
free).  The cells were fixed by adding 4% paraformaldehyde (PFA) for 15 minutes at room 
temperature.  The coverslips were then washed a further three times with PBS and. processed 
to fluorescence microscopy experiments using a Zeiss Axiovert 200 inverted microscope with 
filter for FITC (excitation wavelength 465 – 495 nm, emission wavelength 515 – 555 
nm).  Images were acquired using a Hammamatsu Flash 4 (2048x2048 pixel) camera for each 
channel separately and processed using Volocity Software. 
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